Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.

J. E. Oesterling, M. F. el Etreby, G. J. Gormley, J. L. Imperato-McGinley, Claus Roehrborn, F. H. Schröder, U. W. Tunn

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

In 1993, medical therapy for BPH is a reality. Androgen deprivation therapy (LHRH agonists, antiandrogens, and 5 alpha-reductase inhibitors) has been shown to be effective by reducing the static component of BPH. Of these agents, the 5 alpha-reductase inhibitors have the greatest promise because of their low toxicity profile. Aromatase inhibitors, which function via a different mechanism, however, have not been demonstrated, as monotherapy, to be effective in the treatment of symptomatic BPH. It is still theoretically possible that aromatase inhibitors could have a role in the management of prostatism if they are utilized in conjunction with an antiandrogen or 5 alpha-reductase inhibitor. Although the early results for this endocrine therapies are encouraging, several issues relating to medical treatment remain unanswered. Not everyone with significant prostatism will respond to androgen deprivation therapy. How does the physician identify pre-treatment the patient most likely to achieve a significant improvement in voiding function with 5 alpha-reductase inhibitor therapy? At the present time, there is no method--based on symptoms, DRE findings, serum hormone and PSA levels, or histopathologic criteria--for recognizing the ideal patient for androgen deprivation therapy. Without question, it is a subjective decision. As a result, the benefits and risks of these medical approaches as well as those of the minimally invasive and surgical therapies must be discussed with the patient so that he can participate in the management decision. In this manner, the expectations and needs of the patient will be best served.

Original languageEnglish (US)
Pages (from-to)231-250
Number of pages20
JournalProgress in clinical and biological research
Volume386
StatePublished - 1994

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.'. Together they form a unique fingerprint.

  • Cite this

    Oesterling, J. E., el Etreby, M. F., Gormley, G. J., Imperato-McGinley, J. L., Roehrborn, C., Schröder, F. H., & Tunn, U. W. (1994). Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection. Progress in clinical and biological research, 386, 231-250.